Pharmability

Pharmability (formerly TIRmed Pharma) is a Swedish clinical-stage biotechnology company specializing in the development of novel immunomodulatory treatments for autoimmune skin diseases. The company's lead program, TIR-C, is a topical oligonucleotide-based therapy designed to provide long-lasting relief for patients with atopic dermatitis by targeting underlying immune mechanisms. Headquartered in Stockholm, Pharmability leverages its expertise in immunology to create targeted dermatological immunotherapies that aim to reduce treatment burden and improve patient outcomes. The company is currently advancing TIR-C toward Phase Ib clinical trials and is supported by a network of specialized partners in formulation and manufacturing. Pharmability is backed by life science investors including Sciety and Sciety Venture Partners.